Protein, and therapeutic and cosmetic uses thereof
Inventors
Monsul, Nicholas T. • Berkes, Eva A. • BOEHM, Frederick T. • LIAO, Yu-Hsien
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-12195502-B2
Publication Date
2025-01-14
Expiration Date
Abstract
The present invention provides a novel protein and biologically-active fragments and variants thereof with advantageous therapeutic and cosmetic uses. Also provided are methods of using the proteins, as well as methods of producing the proteins using a recombinant cell. Further provided are recombinant host cells transformed with a polynucleotide sequence that encodes the expression of the proteins.
Core Innovation
The invention relates to a novel Qi611S protein of 74 amino acids (SEQ ID NO: 1) and its nucleotide encoding sequence Qi611s (SEQ ID NO: 2). The Qi611S proteins are produced by recombinant or naturally occurring cells, including Lactobacillus fermentum Qi6 and recombinant E. coli. The document further describes biologically-active fragments and variants of the Qi611S protein.
Qi611S protein and its fragments and variants are presented as modulating signaling pathways that include PPARs (PPARα/β/δ/γ), ERK1/2 via phosphorylated ERK (pERK), and glucocorticoid receptor signaling (GR/phosphorylated GR (pGR)). The document links these pathway modulations to biological outcomes including biofilm inhibition, inflammation and cytokine modulation, cancer-related proliferation effects, and modulation of skin barrier and innate immunity markers.
The document describes application to multiple conditions, including anti-bacterial and anti-biofilm activity, anti-inflammatory activity, metabolism-modulating effects, and anti-cancer and cosmetic benefits associated with Qi611S and its variants. For support, it describes detection and expression of Qi611S and ex vivo and cell-based pathway-related readouts, including increased PPARγ, pERK, and pGR signals, and MRSA biofilm inhibition associated with Qi611S treatment.
Claims Coverage
The independent claim set covers one inventive feature: methods that treat dry eye disease or Meibomian gland dysfunction by administering a therapeutically-effective amount of an isolated Qi611S protein (SEQ ID NO: 1) or a cell expressing that protein. The claim scope includes the therapeutic indication, administration to a subject in need, and specification of the protein sequence as SEQ ID NO: 1.
Treating dry eye disease or Meibomian gland dysfunction by administering an isolated Qi611S protein comprising SEQ ID NO: 1
A method for treating dry eye disease or Meibomian gland dysfunction comprises administering, to a subject in need, a therapeutically-effective amount of an isolated protein or a cell expressing the protein, wherein the protein comprises SEQ ID NO: 1.
Across the independent claim coverage, the inventive focus is the treatment method for dry eye disease or Meibomian gland dysfunction using a therapeutically-effective amount of an isolated Qi611S protein (SEQ ID NO: 1) or a cell expressing that protein. Dependent claims further narrow the treated indication and refine the sequence relationship by specifying that the protein consists of SEQ ID NO: 1.
Stated Advantages
Anti-bacterial and anti-biofilm activity linked to Qi611S proteins and fragments and variants.
Anti-inflammatory and cytokine modulation linked to Qi611S proteins and fragments and variants.
Metabolism-modulating effects linked to Qi611S proteins and fragments and variants.
Anti-cancer effects associated with Qi611S proteins and fragments and variants.
Cosmetic benefits associated with modulation outcomes described for Qi611S proteins and fragments and variants.
Documented Applications
Treating dry eye disease.
Treating Meibomian gland dysfunction.
Interested in licensing this patent?